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Developing feasible strategies and setting realistic targets for disease prevention and control 
depends on representative models, whether conceptual, experimental, logistical or mathematical. 
Mathematical modelling was established in infectious diseases over a century ago, with the 
seminal works of Ross1 and others. Propelled by the discovery of aetiological agents for 
infectious diseases, and Koch’s postulates, models have focused on the complexities of pathogen 
transmission and evolution to understand and predict disease trends in greater depth2. This has 
led to their adoption by policy makers; however, as model-informed policies are being 
implemented, the inaccuracies of some predictions are increasingly apparent, most notably their 
tendency to overestimate the impact of control interventions3-6. Here, we discuss how these 
discrepancies could be explained by methodological limitations in capturing the effects of 
heterogeneity in real-world systems. We suggest that improvements could derive from theory 
developed in demography to study variation in life-expectancy and ageing7. Using simulations, 
we illustrate the problem and its impact, and formulate a pragmatic way forward.  
HETEROGENEITY AFFECTS ACCURACY OF PREDICTIVE MODELS FOR 
DISEASE CONTROL 
We use the examples of acquired immunodeficiency syndrome (AIDS) and coronavirus disease 
2019 (COVID-19) to illustrate the effects that individual variation can have on the performance 
of mathematical models for the dynamics of endemic and epidemic diseases.  
Endemic infectious diseases 
Since the detection of AIDS in the early 1980s, it has been evident that heterogeneity in 
individual sexual behaviours needed to be considered in mathematical models for the 
transmission of the causative agent – the Human Immunodeficiency Virus (HIV)8. Much 
research has been devoted to measuring contact networks in diverse settings and by different 
methods, to attempt to reproduce transmission dynamics accurately9-11. Meanwhile other equally 
important sources of inter-individual variation were overlooked. For example, unmodelled 
heterogeneity in infectiousness and susceptibility led to over-attribution of HIV infectivity to the 
acute phase12 and, consequently, to concerns that interventions relying on treatment as 
prevention might be compromised.  
The problem of unaccounted heterogeneity in predictive models can be illustrated with the 
simplest mathematical description of infectious disease transmission in a host population. Figure 
1 shows the prevalence of infection over time under three alternative scenarios: all individuals 
are at equal risk of acquiring infection (black trajectories [notice unrealistic time scale]); 
individual risk is affected by a factor that modifies either their susceptibility to infection (blue) or 
exposure through connectivity with other individuals (green). Risk modifying factors are drawn 
from a distribution with mean one (blue and green density plots on the left) while the 
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homogeneous scenario is sketched by assigning a factor one to all individuals (black frequency 
plot). As the virus spreads in the human population, individuals at higher risk are predominantly 
infected as indicated at endemic equilibrium (Figure 1 A, B, C, density plots on the right, 
coloured red) and after 100 years of control (Figure 1 D, E, F). The control strategy applied to 
endemic equilibrium in the figure is the 90-90-90 treatment as prevention target advocated by the 
Joint United Nations Programme on HIV/AIDS4 whereby 90% of infected individuals should be 
detected, with 90% of these receiving antiretroviral therapy, and 90% of these should achieve 
viral suppression (becoming effectively non-infectious).  
 
 
Figure 1: Prevalence trajectories under homogeneous and heterogeneous models. Risk distributions are 
simulated in three scenarios: homogeneous (A, D); distributed susceptibility to infection with variance 10 (B, E); 
distributed connectivity with variance 10 (C, F). In disease-free equilibrium, individuals differ in potential risk in 
scenarios B and C, but not in scenario A (risk panels on the left). The vertical lines mark the mean risk values (1 in 
all cases). At endemic equilibrium, individuals with higher risk are predominantly infected (risk panels on the right, 
where red vertical lines mark mean baseline risk among individuals who eventually became infected), resulting in 
reduced mean risk among those who remain uninfected (black vertical lines). To compensate for this selection 
effect, heterogeneous models require a higher 𝑅! to attain the same endemic prevalence (A, B, C). Interventions that 
reduce infection also reduce selection pressure, which unintendedly increases mean risk in the uninfected poll and 
undesirably reduces intervention impact (D, E, F). Models: homogeneous (A, D) 𝑑𝑆 𝑑𝑡⁄ = 𝜇 − 𝛽𝐼𝑆 − 𝜇𝑆, 𝑑𝐼 𝑑𝑡⁄ =𝛽𝐼𝑆 − 𝜇𝐼, and 𝑅! = 𝛽 𝜇⁄ ; heterogeneous susceptibility (B, E) 𝑑𝑆(𝑥) 𝑑𝑡⁄ = 𝑞(𝑥)𝜇 − 𝛽 ∫ 𝐼(𝑢)𝑑𝑢 𝑥𝑆(𝑥) − 𝜇𝑆(𝑥), 𝑑𝐼(𝑥) 𝑑𝑡⁄ = 𝛽 ∫ 𝐼(𝑢)𝑑𝑢 𝑥𝑆(𝑥) − 𝜇𝐼(𝑥), and 𝑅! = 〈𝑥〉𝛽 𝜇⁄ ; heterogeneous connectivity (C, F) 𝑑𝑆(𝑥) 𝑑𝑡⁄ =𝑞(𝑥)𝜇 − 𝛽 ∫𝑢𝐼(𝑢)𝑑𝑢 ∫𝑢𝑞(𝑢)𝑑𝑢⁄ 𝑥𝑆(𝑥) − 𝜇𝑆(𝑥), 𝑑𝐼(𝑥) 𝑑𝑡⁄ = 𝛽∫𝑢𝐼(𝑢)𝑑𝑢 ∫𝑢𝑞(𝑢)𝑑𝑢⁄ 𝑥𝑆(𝑥) − 𝜇𝐼(𝑥), and 𝑅! =〈𝑥"〉𝛽 〈𝑥〉𝜇⁄ . In heterogeneous models, 𝑞(𝑥) is a probability density function with mean 1 and variance 10, and 〈𝑥#〉 
denotes the 𝑖th-moment of the distribution. Gamma distributions were used for concreteness. 
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Figure 1 shows that heterogeneous models that account for wide biological and social variation 
require higher basic reproduction numbers (𝑅!) to reach a given endemic level and predict less 
impact for control efforts when compared with the homogeneous counterpart model. This holds 
true regardless of whether heterogeneity affects susceptibility or connectivity. At endemic 
equilibrium, individuals at higher risk are predominantly infected (red distributions have mean 
greater than one as marked by the red vertical lines), and hence those who remain uninfected are 
individuals with lower risk (blue and green distributions have mean lower than one as marked by 
the black vertical lines). Thus, the mean risk in the uninfected but susceptible subpopulation 
decreases, and the epidemic decelerates (thin blue and green curves); higher values of 𝑅! are 
consequently required if the heterogeneous models are to attain the same endemic level as the 
homogeneous formulation (heavy blue and green curves). Finally, interventions are less 
impactful under heterogeneity because 𝑅! is implicitly higher. Indeed, these biases could help 
explain trends in HIV incidence data which lag substantially behind targets informed by model 
predictions, even in settings that have reached the 90-90-90 implementation targets3,4.  
Epidemic infectious diseases 
A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) isolated at the end of 
2019 from a patient in China has spread worldwide causing the COVID-19 pandemic, despite 
intensive measures to contain the outbreak at the source. Countrywide epidemics have been 
extensively analysed and modelled throughout the world. Initial studies projected attack rates of 
around 90% if transmission had been left unmitigated13, while subsequent reports noted that 
individual variation in susceptibility or exposure to infection might reduce these estimates 
substantially14,15 and skew epidemic curves (compare the blue [heterogeneous susceptibility] and 
green [heterogeneous connectivity] curves with the black [homogeneous]). 
 
Figure 2: Incidence trajectories under homogeneous and heterogeneous models. Risk distributions are 
simulated in three scenarios: homogeneous (black); distributed susceptibility to infection with variance 10 (blue); 
distributed connectivity with variance 10 (green). Left panels represent distributions of potential individual risk prior 
to the outbreak, with vertical lines marking mean risk values (1 in all cases). As the epidemic progresses, individuals 
with higher risk are predominantly infected, depleting the susceptible pool in a selective manner and decelerating the 
epidemic. The inset overlays the three epidemic curves scaled to the same height to facilitate shape comparison. 
Right panels show in red the risk distributions among individuals who have been infected over 4 months of epidemic 
spread (mean greater than one when risk is heterogeneous, as marked by red vertical lines) and the reduced mean 
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risk among those who have not been affected (black vertical lines). Models: homogeneous (black) 𝑑𝑆 𝑑𝑡⁄ = −𝛽𝐼𝑆, 𝑑𝐼 𝑑𝑡⁄ = 𝛽𝐼𝑆 − 𝛾𝐼, and 𝑅! = 𝛽 𝛾⁄ ; heterogeneous susceptibility (blue) 𝑑𝑆(𝑥) 𝑑𝑡⁄ = −𝛽 ∫ 𝐼(𝑢)𝑑𝑢 𝑥𝑆(𝑥), 𝑑𝐼(𝑥) 𝑑𝑡⁄ = 𝛽 ∫ 𝐼(𝑢)𝑑𝑢 𝑥𝑆(𝑥) − 𝛾𝐼(𝑥), and 𝑅! = 〈𝑥〉𝛽 𝛾⁄ ; heterogeneous connectivity (green) 𝑑𝑆(𝑥) 𝑑𝑡⁄ =−𝛽 ∫𝑢𝐼(𝑢)𝑑𝑢 ∫𝑢𝑞(𝑢)𝑑𝑢⁄ 𝑥𝑆(𝑥), 𝑑𝐼(𝑥) 𝑑𝑡⁄ = 𝛽 ∫𝑢𝐼(𝑢)𝑑𝑢 ∫𝑢𝑞(𝑢)𝑑𝑢⁄ 𝑥𝑆(𝑥) − 𝛾𝐼(𝑥), and 𝑅! = 〈𝑥"〉𝛽 〈𝑥〉𝛾⁄ . In 
heterogeneous models, 𝑞(𝑥) is a probability density function with mean 1 and variance 10, and 〈𝑥#〉 denotes the 𝑖th-
moment of the distribution. Gamma distributions were used for concreteness. 
As models inform policies, we cannot but stress the importance of representing individual 
variation pragmatically. While much is being discovered about SARS-CoV-2 and its interaction 
with human hosts, epidemic curves are widely available from locations where the virus has been 
circulating. Models can be constructed with inbuilt risk distributions whose shape can be inferred 
by assessing their ability to mould simulated trajectories to observed epidemics while accounting 
for realistic social distancing interventions6. 
Variation in infectiousness was critical to attribute the scarce and explosive outbreaks to 
superspreaders when the first SARS emerged in 200216, but what we are discussing here is 
different. Infectiousness does not respond to selection as susceptibility or connectivity do, i.e. 
models with and without variation in infectiousness perform equivalently when implemented 
deterministically and only differ through stochastic processes.  
The need to account for heterogeneity in risk to acquire infections is not restricted to AIDS and 
COVID-19 but is generally applicable across infectious disease epidemiology models. Moreover, 
similar issues arise in methods intended to evaluate the efficacy interventions from experimental 
studies as illustrated for vaccines in the sequel. 
HETEROGENEITY AND VACCINE EFFICACY OVER TIME AND ACROSS 
SETTINGS 
Individual variation in susceptibility to infection induces biases in cohort studies and clinical 
trials. Vaccine efficacy trials offer a useful illustration of the problem and give insight into the 
potential solution. In a vaccine trial, two groups of individuals are randomised to receive a 
vaccine or placebo and disease occurrences are recorded in each group. As disease affects 
predominantly higher-risk individuals, the mean risk among those who remain unaffected 
decreases and disease incidence declines. In the vaccine group the same trend will occur at a 
slower pace (presuming that the vaccine protects to some degree). As a result, the two 
randomised groups become different over time with more highly susceptible individuals 
remaining in the vaccine group. The vaccine efficacy, described as a ratio of cases in vaccinated 
compared to control group, therefore appears to wane (Figure 3)17,18. This effect will be stronger 
in settings where transmission intensity is higher, inducing a trend of seemingly declining 
efficacy with disease burden19. The concept is illustrated in Figure 3 by simulating a vaccine trial 
with heterogeneous and homogeneous models analogous to those utilised in Figures 1 and 2.  
Selection on individual variation in disease susceptibility thus offers an explanation for vaccine 
efficacy trends that is entirely based on population level heterogeneity, in contrast with waning 
vaccine-induced immunity, an individual-level effect20. As both processes may occur 
concurrently in a trial, it is important to disentangle their roles, as they lead to different 
interpretations of the same incidence trend. For example, vaccine efficacy might wane in all 
individuals, or it might be constant for each individual but decline at the population level due to 
selection on individual variation. To capture this in a timely manner requires multicentre trial 
designs with sites carefully selected over a gradient of transmission intensities (e.g. optimally 
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spaced along the incidence axis in Figure C, F), and analyses performed by fitting curves 
generated by models that incorporate individual heterogeneity. An alternative and more tightly 
controlled approach would be to use experimental designs in human infection challenge studies 
where these are available21 to generate dose-response curves and apply similar models. These 
approaches have recently been successfully tested in animal systems22. 
 
Figure 3: Vaccine efficacy trajectories under homogeneous and heterogeneous models. A,B,C, Heterogeneous 
susceptibility or connectivity (gamma-distributed with mean 1 and variance 10); D,E,F, Homogeneous model. 
Models: (homogeneous) 𝑑𝑆& 𝑑𝑡⁄ = −𝜆𝑆&, 𝑑𝐼& 𝑑𝑡⁄ = 𝜆𝑆&, and 𝑑𝑆' 𝑑𝑡⁄ = −𝜎𝜆𝑆', 𝑑𝐼' 𝑑𝑡⁄ = 𝜎𝜆𝑆'; (heterogeneous) 𝑑𝑆&(𝑥) 𝑑𝑡⁄ = −𝜆𝑥𝑆&(𝑥), 𝑑𝐼&(𝑥) 𝑑𝑡⁄ = 𝜆𝑥𝑆&(𝑥), and 𝑑𝑆'(𝑥) 𝑑𝑡⁄ = −𝜎𝜆𝑥𝑆'(𝑥), 𝑑𝐼'(𝑥) 𝑑𝑡⁄ = 𝜎𝜆𝑥𝑆'(𝑥). Vaccine 
efficacy is calculated as [1 − 𝑟'(𝑡) 𝑟&⁄ (𝑡)] × 100, where 𝑟' and 𝑟& represent the incidences in vaccinated and control 
group, respectively: (homogeneous) 𝑟&(𝑡) = 𝜆; 𝑟'(𝑡) = 𝜎𝜆; (heterogeneous) 𝑟&(𝑡) = 𝜆 ∫ 𝑥𝑆&(𝑥, 𝑡)𝑑𝑥 ∫ 𝑆&(𝑥, 𝑡)𝑑𝑥⁄ ; 𝑟'(𝑡) = 𝜎𝜆 ∫𝑥𝑆'(𝑥, 𝑡)𝑑𝑥 ∫ 𝑆'(𝑥, 𝑡)𝑑𝑥⁄ . 
INDIVIDUAL HETEROGENEITIES AND THEIR INFERENCES USING RISK 
INEQUALITY METRICS 
Heterogeneities in predispositions to infection depend on the mode of transmission but play a 
role in all high-burden infectious diseases. In respiratory infections, heterogeneity may arise 
from a variation in exposure of the susceptible host to the pathogen, or the competence of host 
immune systems to control pathogenic viruses or bacteria. These two processes have multiple 
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component factors. Some of the most studied are age, patterns of inter-personal contacts, 
exposure to smoke, nutritional status, pre-existing respiratory illness such as asthma or chronic 
obstructive pulmonary disease, and the presence of other concomitant diseases such as diabetes 
and HIV. Enteric diseases have different heterogeneities determined by the source and dose of 
contaminated sources. Vector-borne parasites, viruses and bacteria may be transmitted by 
mosquitoes, ticks, snails, and other intermediate hosts, where the risk of onward transmission is 
affected by heterogeneities in exposure and susceptibility across a complex range of host, 
demographic, environmental and social factors.  
The mechanisms underpinning single factors for infection and their interactions determine 
individual propensities to acquire disease. These are potentially so numerous that to attain a full 
mechanistic description may be unfeasible. Even in the unlikely scenario that a list of all putative 
factors may be available, the measurement of effect sizes would be subject to selection within 
cohorts resulting in underestimated variances23. To contribute constructively to the development 
of health policies, model building involves compromises between leaving factors out 
(reductionism) or adopting a broader but coarse description (holism). Holistic descriptions of 
heterogeneity are currently underutilised in infectious diseases. 
Recently, measures of statistical dispersion commonly used in economics have been adapted to 
describe risk inequality in cancer24, tuberculosis25 and malaria26, offering a holistic approach to 
improve the predictive capacity of disease models. Essentially, this involves stratifying the 
population into groups of individuals with similar risk, which may be as granular as individual 
level for frequent diseases, such as malaria or influenza. For infectious diseases which cluster by 
proximity, such as tuberculosis, stratification can use geographical units. Familial relatedness 
pertains when there is a clear genetic contribution to risk, such as cancer. By recording disease 
events in each group, specific incidence rates can be calculated and ranked. Unknown 
distributions of individual risk are then embedded in dynamic models and estimated by fitting the 
models to the stratified data. Because they incorporate explicit distributions of individual risk, 
these models automatically adjust average risks in susceptible pools to changes in transmission 
intensity, occurring naturally or in response to interventions. Not subject to the selection biases 
described above, this model approach inherently enables more accurate impact predictions for 
use in policy development.   
CONCLUSION  
There is compelling evidence that epidemiologists could use indicators that account for the 
whole variation in disease risk. Heterogeneity is unlimited in real-world systems and cannot be 
completely reconstructed mechanistically. Inspired by established practices in demography and 
economics and supported by successful applications in both infectious and non-communicable 
diseases, the use and further development of these approaches offers a powerful route to build 
disease models that enable more accurate estimates of intervention efficacy and more accurate 
predictions of the impact of control programmes. 
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